Year: 2022

Data to be featured in one poster and two oral presentations WATERTOWN, Mass., Oct. 11, 2022 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company pioneering precision immune tolerance with its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, today announced three upcoming presentations, including one joint presentation with our partner AskBio, at the 29th Annual European Society of Gene and Cell Therapy (ESGCT) Conference, to be held virtually and in-person from October 11-14 in Edinburgh, United Kingdom. These presentations demonstrate the therapeutic utility of Selecta’s immune tolerance platform, ImmTOR®, to enable safe repeated vector doses and mitigate unwanted immune responses to AAV capsids. “We are thrilled to present data demonstrating the power...

CALGARY, Alberta, Oct. 11, 2022 (GLOBE NEWSWIRE) — Pan American Energy Corp. (the “Company” or “Pan American”) (CSE: PNRG) (OTC PINK: GSUXF) (FSE: SS6) wishes to announce that its common shares commenced trading on the Frankfurt Stock Exchange (“FSE”) on October 10, 2022 under the symbol “SS6” with ISIN CA69783Y1034. “The FSE is the world’s third-largest organized trading market in terms of turnover and dealing in securities behind the New York Stock Exchange and NASDAQ,” commented Jason Latkowcer, CEO of Pan American. “We are very happy to broaden Pan American’s access to the European capital markets. We believe the listing of the Company’s shares on the FSE will increase our shareholder base, create greater liquidity, and increase overall market awareness of our projects.” The Company’s common shares are now cross-listed on the...

Two Presentations Featuring Thin Film Freezing Technology Selected for the Meeting’s Special Poster Collections Demonstrates Use of Thin Film Freezing to Produce Dry Powder Inhaled Formulations of Monoclonal Antibodies and Applications of Machine Learning to Predict Aerosol Performance of Dry Powders for Inhalation Highlights the Company’s Strategic Focus of Expanding its Biologics Product Portfolio FORT WORTH, Texas, Oct. 11, 2022 (GLOBE NEWSWIRE) — TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today shared further details on the poster presentations featuring the Company’s Thin Film Freezing Technology at the American Association of Pharmaceutical Scientists...

Collaboration Streamlines Clinical Trial Tokenization, Further Empowers Medical Affairs, Market Access, HEOR and Commercial Analytics for Clients MORRISVILLE, N.C., Oct. 11, 2022 (GLOBE NEWSWIRE) — Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced an expanded partnership with Datavant, the leader in helping organizations securely connect health data. The increasing collaboration between the companies will further leverage the full suite of capabilities in Datavant Switchboard and Datavant’s large data ecosystem to accelerate the clinical development and commercialization of new therapies for patients. Syneos Health and Datavant have a long-standing strategic partnership, and through this expanded relationship, Syneos Health will use Datavant Switchboard to develop...

Sanoma Corporation, Press Release, 11 October 2022 at 14:00 EET Sanoma will publish its Q3 2022 Interim Report on 27 October Sanoma will publish its Interim Report for January 1 – 30 September 2022 on Thursday 27 October 2022 approx. at 8:30 EET. The report and related materials will be available on www.sanoma.com/en/investors after publishing. An analyst and investor conference will be held in English by the President and CEO Susan Duinhoven and CFO Alex Green the same day at 11:00 EET at Sanomatalo, Flik Studio Eliel, 1st floor, Töölönlahdenkatu 2, Helsinki. To join the event, please register by email to ir@sanoma.com latest on Tuesday 25 October 2022. The conference can be followed as a live webcast at https://sanoma.videosync.fi/2022-q3-results. Management presentation is followed by a Q&A session. Questions can be placed through...

Arecor Therapeutics plc(“Arecor”, the “Company” or the “Group”) HEADLINE RESULTS FROM PHASE I CLINICAL TRIAL OF ULTRA-RAPID ACTING INSULIN CANDIDATE AT247 DEMONSTRATE SIGNIFICANTLY ACCELERATED INSULIN ABSORPTION AND EARLY EXPOSURE COMPARED TO GOLD STANDARD INSULINS NOVOLOG® AND FIASP®AT247 delivers significantly accelerated insulin absorption and early exposure (PK profile) compared with NovoLog® and Fiasp®, meeting co-primary endpoint AT247 delivers a statistically significant superior glucose lowering effect compared with NovoLog® supporting the accelerated absorption and early exposure PK profile AT247 demonstrated a similar PD profile to Fiasp®. The statistically superior co-primary endpoint was not met AT247 shown to be safe and efficacious when delivered by continuous subcutaneous (SC) infusion Further supports potential to enable...